Stock Events

Stock Events

Poniard Pharmaceuticals 

$0.000100
2
+$0.00+0% Friday 20:00

Statistics

Day High
0.0001
Day Low
0.0001
52W High
0.0001
52W Low
0.00001
Volume
7
Avg. Volume
47
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

31OctExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
0
0.33
0.67
1
Expected EPS
0
Actual EPS
0

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap196.12B
Amgen is a biotechnology firm focused on human therapeutics, directly competing in the oncology segment with Poniard Pharmaceuticals.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio in cancer drugs, overlapping with Poniard's focus on oncology treatments.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is involved in the development and commercialization of various pharmaceuticals, including cancer treatments, which competes with Poniard's oncology products.
Merck
MRK
Mkt Cap305.12B
Merck is a leading pharmaceutical company with a significant presence in the oncology market, directly competing with Poniard Pharmaceuticals in cancer treatment solutions.
Lilly(Eli) &
LLY
Mkt Cap1.06T
Eli Lilly and Company develops and sells pharmaceutical products, including cancer therapies, competing in the same space as Poniard Pharmaceuticals.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is a biopharmaceutical company that develops and markets therapies in areas including oncology, competing with Poniard's cancer focus.
Novartis
NVS
Mkt Cap293.94B
Novartis is a global healthcare company that manufactures drugs, including those for cancer, which places them in direct competition with Poniard Pharmaceuticals.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca operates in various therapeutic areas, including oncology, making them a competitor to Poniard Pharmaceuticals in the cancer drug market.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG focuses extensively on oncology drug development and marketing, competing with Poniard Pharmaceuticals in the cancer treatment arena.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson engages in the creation of pharmaceuticals, including oncology drugs, competing with Poniard Pharmaceuticals in the healthcare sector.

About

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Show more...
CEO
Dr. Robert F. Caspari
Employees
7
Country
United States
ISIN
US7324494001

Listings

STU
DE
NX1B.STU
OTC Link
US
PARD

0 Comments

Share your thoughts

FAQ

What is Poniard Pharmaceuticals stock price today?▼
The current price of PARD is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Poniard Pharmaceuticals stock price performance more closely on the chart.
What is Poniard Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Poniard Pharmaceuticals stocks are traded under the ticker PARD.
Is Poniard Pharmaceuticals stock price growing?▼
PARD stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Poniard Pharmaceuticals has showed a +0% increase.
What were Poniard Pharmaceuticals earnings last quarter?▼
PARD earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does Poniard Pharmaceuticals have?▼
As of July 14, 2026, the company has 7 employees.
In which sector is Poniard Pharmaceuticals located?▼
Poniard Pharmaceuticals operates in the Health & Wellness sector.
When did Poniard Pharmaceuticals complete a stock split?▼
The last stock split for Poniard Pharmaceuticals was on November 23, 2011 with a ratio of 1:40.
Where is Poniard Pharmaceuticals headquartered?▼
Poniard Pharmaceuticals is headquartered in Seattle, United States.